沃森生物(300142.SZ):公司產品不存在捆綁銷售的情況
格隆匯8月2日丨有投資者向沃森生物(300142.SZ)提問,“首先可轉債的推進是否能加快進度?從去年出的方案直到今天還沒審核通過,是否項目有重大的不確定性?最近友商萬泰生物116元中標廣東省二價疫苗,是否存在低價壟斷市場行為?公司面臨如此巨大的壓力情況下,是否改變銷售策略,比如肺炎疫苗和二價疫苗捆綁銷售給各個銷售商?公司能否結合沃森自身情況推出有利於促進消費的銷售方案?”
沃森生物回覆稱,公司本次可轉債發行事項尚需通過深交所審核,並獲得中國證券監督管理委員會作出同意註冊的決定後方可實施,最終需要以審批結果為準,公司產品不存在捆綁銷售的情況,後續競爭策略會根據市場情況持續動態調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.